Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413827 · ClinicalTrials.gov registry record · Phase 1
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
A Phase 1 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02413827 is a Phase 1 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT02413827, a Phase 1 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.
Interventions
- DRUG Combination of varlilumab and ipilimumab
- DRUG Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413827
The ClinicalTrials.gov registry entry for NCT02413827 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Combination of varlilumab and ipilimumab is the first listed.
NCT02413827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02413827 about?
NCT02413827 is a clinical study titled "A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma". This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.
What is the current status of trial NCT02413827?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-04. Estimated completion is 2016-11-09.
What interventions are being tested in trial NCT02413827?
The interventions under investigation include: Combination of varlilumab and ipilimumab (DRUG), Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC (DRUG).
Who is sponsoring clinical trial NCT02413827?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.